1 magnificent ASX stock down 10% to buy and hold forever

Analysts say this high-quality stock is a great option for investors right now.

| More on:
A smiling woman sits in a cafe reading a story on her phone about Rio Tinto and drinking a coffee with a laptop open in front of her.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been an uncharacteristically underwhelming 12 months for CSL Ltd (ASX: CSL) shares.

Over the period, the ASX biotech stock has lost around 10% of its value.

As a comparison, over the past 15 years, this magnificent company's shares have generated an average total return of 16.6% per annum.

This would have turned a $10,000 investment in the ASX stock back in 2009 into $100,000 today.

And while recent weakness is very off-brand for CSL and disappointing for shareholders, it could prove to be a buying opportunity for non-shareholders.

A large number of analysts share this view. They currently have buy ratings on the company's shares and price targets that suggest market-beating returns are possible.

What are analysts saying about this ASX stock?

One broker that is particularly bullish on CSL is Morgans. In fact, the broker has named the company on its best ideas list again this month. It has an add rating and a $315.40 price target on it, which implies a potential upside of almost 13% over the next 12 months.

It highlights the company's shares are undervalued compared to historical averages. This is despite the ASX stock having a very bright outlook. It said:

While shares have struggled of late, we continue to view CSL as a key portfolio holding and sector pick, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares trading at 25x, a substantial discount (20%) to its long-term average.

Analysts at Macquarie are even more bullish on the ASX stock. They currently have an outperform rating and a $330.00 price target on CSL's shares. This suggests that an upside of 18% is possible between now and this time next year.

The broker is very positive on the company's outlook. So much so that it sees scope for CSL's shares to rise to $500 within three years. This is almost double its current share price, which means that if Macquarie is on the money with its recommendation, investors will see some very big annual returns over the next three years.

In addition, the team at UBS remains very positive. Last month it retained its buy rating and $330.00 price target on CSL's shares. UBS believes the ASX stock can achieve high-teens earnings growth over the next few years.

All in all, the broker community believes this magnificent ASX stock could be worth buying and holding at current levels.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Buy, hold or sell these 3 ASX 200 healthcare shares: Experts

These experts reveal their calls on CSL, Resmed and Sonic Healthcare shares today.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Share Gainers

Guess which ASX healthcare stock just exploded 63% on Federal budget funding news!

Investors are bidding up the ASX healthcare stock amid extra funding in the Federal budget.

Read more »

two doctors smile as they sit together at a desk looking at a patient's Xray.
Healthcare Shares

This ASX 200 healthcare stock just hit an all-time high: Is it too late to buy?

The valuation of this high-performer has soared.

Read more »

ventilator mask
Healthcare Shares

3 reasons ResMed shares 'are just too cheap!'

This stock could still produce healthy gains, according to one fund manager.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

2 ASX healthcare shares rocking higher on big news

This 'spray-on skin' company and cancer-fighting biotech have exciting news for shareholders today.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Insider still buying Mesoblast shares despite 230% rise this year: Should you buy?

This high-flying share is still reporting insider buying. Should you buy too?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Buy CSL shares for growing dividends and 'compelling long-term tailwinds'

CSL has increased both its interim and final dividend every year since 2021.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Resmed share price higher despite CEO hitting sell on 14,683 shares

ResMed's CEO just sold $4.8 million worth of his own company's shares.

Read more »